EMA Authorised: Siklos (hydroxycarbamide) — Theravia

View source ↗

Summary

EMA authorised Siklos (hydroxycarbamide) by Theravia for use in sickle cell disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• SIKLOS (Hydroxyurea)

Snippet

Status: Authorised. Therapeutic area: Anemia, Sickle Cell. MAH: Theravia. Decision date: 11/02/2026